Clinical Trials
25 trialsLow-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
SINE
University of Chicago
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
National University Hospital, Singapore
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
Karyopharm Therapeutics Inc
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
KPT-330
Ohio State University Comprehensive Cancer Center
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
KPT-330+RICE
Weill Medical College of Cornell University
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
SELINDA
The Lymphoma Academic Research Organisation
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
University of Chicago
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
National Cancer Centre, Singapore
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Memorial Sloan Kettering Cancer Center
Phase I Study of KPT330 in Asian Patients
National University Hospital, Singapore
FLAGINEXOR
PETHEMA Foundation
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
University of Chicago
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center